Zusammenfassung

• Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
  • Wikiderm.EntryClass[0]

Details

Wikiderm.EntryClass[0]

Eintrag

...	...	@@ -59,13 +59,19 @@
59	59	(% class="Bullet" %)-(%%) Pyoderma gangraenosum
60	60
61	61	(% class="Eintrag-2" %)
62		-(% class="Feature" %)TF:(%%) Infekte
	62	+(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
63	63
64	64	(% class="Ebene-2" %)
65	65	(% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66	66
	67	+(% class="Ebene-1" %)
	68	+(% class="Bullet" %)-(%%) Dupilumab
	69	+
	70	+(% class="Ebene-2" %)
	71	+(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
	72	+
67	67	(% class="Eintrag-2" %)
68		-(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)
	74	+(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
69	69
70	70	(% class="Ebene-1" %)
71	71	(% class="Bullet" %)-(%%) Dermatitis herpetiformis
...	...	@@ -79,11 +79,14 @@
79	79	(% class="Ebene-1" %)
80	80	(% class="Bullet" %)-(%%) Pemphigus foliaceus
81	81
82		-(% class="Eintrag-2" %)
	88	+(% class="Ebene-1" %)
	89	+(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
83	83
	91	+(% class="Ebene-2" %)
	92	+(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
84	84
85		-(% class="Ebene-1" %)
86		-(% class="Bullet" %)-(%%) Psoriasis pustulosa
	94	+(% class="Ebene-2" %)
	95	+(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
87	87
88	88	(% class="Ebene-1" %)
89	89	(% class="Bullet" %)-(%%) Tinea incognito
...	...	@@ -103,6 +103,9 @@
103	103	(% class="Ebene-1" %)
104	104	(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
105	105
	115	+(% class="Ebene-1" %)
	116	+(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
	117	+
106	106	(% class="Eintrag-2" %)
107	107	(% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
108	108
...	...	@@ -110,6 +110,12 @@
110	110	(% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
111	111
112	112	(% class="Ebene-2" %)
	125	+(% class="Bullet" %)-(%%) Mometasonfuroat
	126	+
	127	+(% class="Ebene-3" %)
	128	+(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
	129	+
	130	+(% class="Ebene-2" %)
113	113	(% class="Bullet" %)-(%%) Tacalcitol
114	114
115	115	(% class="Ebene-3" %)
...	...	@@ -116,7 +116,7 @@
116	116	(% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
117	117
118	118	(% class="Ebene-3" %)
119		-(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
	137	+(% class="Feature" %)PT:(%%) CR
120	120
121	121	(% class="Ebene-3" %)
122	122	(% class="Feature" %)Altn:(%%) Maxacalcitol
...	...	@@ -125,7 +125,7 @@
125	125	(% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
126	126
127	127	(% class="Ebene-5" %)
128		-(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
	146	+(% class="Feature" %)Lit:(%%) CR
129	129
130	130	(% class="Ebene-2" %)
131	131	(% class="Bullet" %)-(%%) Dapson Gel
...	...	@@ -140,7 +140,7 @@
140	140	(% class="Bullet" %)-(%%) Dapson
141	141
142	142	(% class="Ebene-3" %)
143		-(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
	161	+(% class="Feature" %)Bed:(%%) GS
144	144
145	145	(% class="Ebene-3" %)
146	146	(% class="Feature" %)Dos:(%%) 100-150 mg/Tag
...	...	@@ -179,8 +179,11 @@
179	179	(% class="Bullet" %)-(%%) Apremilast
180	180
181	181	(% class="Ebene-3" %)
182		-(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
	200	+(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
183	183
	202	+(% class="Ebene-3" %)
	203	+(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
	204	+
184	184	(% class="Ebene-2" %)
185	185	(% class="Bullet" %)-(%%) Anti-TNF-alpha
186	186
...	...	@@ -188,14 +188,8 @@
188	188	(% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
189	189
190	190	(% class="Ebene-4" %)
191		-(% class="Feature" %)Phar:(%%) Remicade^^®^^
	212	+(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
192	192
193		-(% class="Ebene-4" %)
194		-(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
195		-
196		-(% class="Ebene-4" %)
197		-(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
198		-
199	199	(% class="Ebene-3" %)
200	200	(% class="Bullet" %)-(%%) Adalimumab
201	201
...	...	@@ -203,7 +203,7 @@
203	203	(% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich)
204	204
205	205	(% class="Ebene-5" %)
206		-(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
	221	+(% class="Feature" %)PT:(%%) CR
207	207
208	208	(% class="Ebene-2" %)
209	209	(% class="Bullet" %)-(%%) Guselkumab
...	...	@@ -210,3 +210,4 @@
210	210
211	211	(% class="Ebene-3" %)
212	212	(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
	228	+